Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Schreiber AR, Nguyen A, Bagby SM, Arcaroli JJ, Yacob BW, Quackenbush K, Guy JL, Crowell T, Stringer B, Danaee H, Kalebic T, Messersmith WA, Pitts TM.

Clin Cancer Drugs. 2018;5(1):42-49. doi: 10.2174/2212697X05666180516120907.

2.

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.

Gallery M, Zhang J, Bradley DP, Brauer P, Cvet D, Estevam J, Danaee H, Greenfield E, Li P, Manfredi M, Loke HK, Rabino C, Stringer B, Williamson M, Wyant T, Yang J, Zhu Q, Abu-Yousif A, Veiby OP.

PLoS One. 2018 Jan 25;13(1):e0191046. doi: 10.1371/journal.pone.0191046. eCollection 2018.

3.

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers.

Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, Gao F, Trepicchio WL, Rugge M.

PLoS One. 2017 Dec 19;12(12):e0189953. doi: 10.1371/journal.pone.0189953. eCollection 2017.

4.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

5.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T.

Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19.

PMID:
28527133
6.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.

Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T.

Cancer Res Treat. 2018 Apr;50(2):398-404. doi: 10.4143/crt.2017.074. Epub 2017 May 10.

7.

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS.

JMIR Res Protoc. 2017 Mar 20;6(3):e45. doi: 10.2196/resprot.7289.

8.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T.

Invest New Drugs. 2017 Apr;35(2):235-241. doi: 10.1007/s10637-017-0439-y. Epub 2017 Feb 11.

PMID:
28188407
9.

Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.

Bahamon BN, Gao F, Danaee H.

Arch Pathol Lab Med. 2016 Dec;140(12):1397-1403. Epub 2016 Sep 9.

PMID:
27610644
10.

Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.

Venkatakrishnan K, Zhou X, Ecsedy J, Mould DR, Liu H, Danaee H, Fingert H, Kleinfield R, Milton A.

J Clin Pharmacol. 2015 Mar;55(3):336-47. doi: 10.1002/jcph.410. Epub 2014 Nov 18.

PMID:
25302940
11.

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP.

Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20.

12.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH.

J Clin Oncol. 2014 Jan 1;32(1):44-50. doi: 10.1200/JCO.2012.46.8793. Epub 2013 Sep 16.

13.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC.

Blood. 2012 Nov 29;120(23):4513-6. doi: 10.1182/blood-2012-05-426924. Epub 2012 Sep 27.

14.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ.

Gynecol Oncol. 2012 Oct;127(1):63-9. doi: 10.1016/j.ygyno.2012.06.040. Epub 2012 Jul 5.

PMID:
22772063
15.

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA.

Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10.

16.

Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition.

Estevam J, Danaee H, Liu R, Ecsedy J, Trepicchio WL, Wyant T.

J Immunol Methods. 2011 Jan 5;363(2):135-42. doi: 10.1016/j.jim.2010.09.021. Epub 2010 Sep 29.

PMID:
20887727
17.

Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J.

Mol Cancer Ther. 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. Epub 2010 Aug 19.

18.

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.

Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H.

Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54. doi: 10.1007/s00280-010-1377-y. Epub 2010 Jul 7.

19.

Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin.

Danaee H, Karagas MR, Kelsey KT, Perry AE, Nelson HH.

J Invest Dermatol. 2006 May;126(5):1152-8.

20.

Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.

Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT.

Cancer Res. 2005 Aug 15;65(16):7081-5.

21.

Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.

Marsit CJ, Okpukpara C, Danaee H, Kelsey KT.

Mol Carcinog. 2005 Oct;44(2):146-50.

PMID:
16013053
22.

Carcinogen exposure and gene promoter hypermethylation in bladder cancer.

Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT.

Carcinogenesis. 2006 Jan;27(1):112-6. Epub 2005 Jun 29.

PMID:
15987713
23.
24.

Microsatellite instability at tetranucleotide repeats in skin and bladder cancer.

Danaee H, Nelson HH, Karagas MR, Schned AR, Ashok TD, Hirao T, Perry AE, Kelsey KT.

Oncogene. 2002 Jul 25;21(32):4894-9.

25.

Analysis of air pollution particulate-mediated oxidant stress in alveolar macrophages.

Goldsmith CA, Imrich A, Danaee H, Ning YY, Kobzik L.

J Toxicol Environ Health A. 1998 Aug 7;54(7):529-45.

PMID:
9726778
26.

Functional characterization of rat chemokine macrophage inflammatory protein-2.

Frevert CW, Farone A, Danaee H, Paulauskis JD, Kobzik L.

Inflammation. 1995 Feb;19(1):133-42.

PMID:
7535749
27.

Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation.

Frevert CW, Huang S, Danaee H, Paulauskis JD, Kobzik L.

J Immunol. 1995 Jan 1;154(1):335-44.

PMID:
7995953
28.

Methyl farnesoate levels in male spider crabs exhibiting active reproductive behavior.

Sagi A, Ahl JS, Danaee H, Laufer H.

Horm Behav. 1994 Sep;28(3):261-72.

PMID:
7814006

Supplemental Content

Loading ...
Support Center